Advanced Neurosciences Inst — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$18,852	1
2023	Research	$27,043	5
2022	Research	$247,851	18
2021	Research	$147,015	17
2020	Research	$116,648	15
2019	Research	$72,070	11

Breakdown

Who paid Research payments · program years 2019–2024

Genzyme Corporation $605,928 60 payments
Adamas Pharmaceuticals, Inc. $23,551 7 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $274,585 17 payments
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $87,515 7 payments
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) $67,850 17 payments
A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) $62,754 5 payments
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $45,571 3 payments
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multi $32,125 4 payments
A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $18,896 2 payments
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $18,400 2 payments
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) $9,200 1 payment
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) $4,676 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.